| Gene symbol | GH1 | Synonyms | GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B, IGHD2, hGH-N | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q23.3 | dbXrefs | |
| Description | growth hormone 1 | ||||
| Gene symbol | LIPF | Synonyms | GL, HGL, HLAL | Type of gene | protein-coding |
| Chromosome | 10 | Map location | 10q23.31 | dbXrefs | |
| Description | lipase F, gastric type | ||||
| Gene symbol | UL128 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 | dbXrefs | |
| Description | contains signal peptide; similar to CC chemokines; complexed with envelope glycoproteins H and L; essential in non-fibroblast cells; involved in cell entry | ||||
| Gene symbol | UL130 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 (176984..177628, complement) | dbXrefs | |
| Description | envelope glycoprotein UL130 | ||||
| Gene symbol | UL131A | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 (177649..178146, complement) | dbXrefs | |
| Description | envelope protein UL131A | ||||
| GTO ID | GTC2832 |
| Trial ID | NCT05105048 |
| Disease | Human Cytomegalovirus Infection |
| Altered gene | gB|gH|gL|UL128|UL130|UL131A |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1647 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 When Administered to Healthy Japanese Adults (18-40 Years of Age) in the United States |
| Year | 2021 |
| Country | United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1647-P103 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1647 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||